Value through Innovation01 July 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
01.07.2015

Boehringer Ingelheim Animal Health: 2015 European PRRS Research Award open for submissions until July 31st

22.06.2015

Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study

16.06.2015

New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers

08.06.2015

Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care

08.06.2015

Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA

03.06.2015

NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication

03.06.2015

Respimat® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim

31.05.2015

ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung

28.05.2015

Type 2 diabetes: Synjardy® (empagliflozin/metformin hydrochloride) approved in the European Union

28.05.2015

Boehringer Ingelheim and researchers at The University of Michigan collaborate to study mechanisms of diabetic nephropathy in Pima Indians

27.05.2015

Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s® 75th Scientific Sessions

26.05.2015

FDA approves Boehringer Ingelheim’s Stiolto™* Respimat® as once-daily maintenance treatment for COPD

-  
21.05.2015

Eureka Therapeutics Inc. and Boehringer Ingelheim Announce a Collaboration to Identify Next Generation Antibodies for Cancer Treatment

20.05.2015

Boehringer Ingelheim welcomes the update of the ATS/ERS/JRS/ALAT 2011 evidence based guidelines for treatment of idiopathic pulmonary fibrosis (IPF), suggesting nintedanib* for the treatment of IPF.

20.05.2015

New data show benefit of tiotropium/olodaterol Respimat® from the start of COPD maintenance therapy1,2,3

-  
18.05.2015

New data and analyses confirm the efficacy and safety of OFEV® (nintedanib*) for the treatment of IPF beyond 52 weeks and for distinct subgroups

18.05.2015

Data Comparison shows onset of action of oral hyoscine butylbromide already as early as 15 minutes

18.05.2015

Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16